RegeneRX Biopharmaceuticals Inc (CE) (RGRX) Cours

Form 15-12G - Securities registration termination [Section 12(g)]

Form 8-K - Current report

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cel...

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure Functional...

RegeneRx to Present at 2 Investor Conferences

RegeneRx to Present at 2 Investor Conferences PR Newswire ROCKVILLE, Md., May 22, 2015 ROCKVILLE, Md., May 22, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a...

Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology

Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology Statistically Significant Findings Identify Key Efficacy Targets for Phase IIb/III Clinical...

Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral...

Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function PR Newswire ROCKVILLE...